Curis Inc (CRIS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Curis Inc (CRIS) has a cash flow conversion efficiency ratio of -0.708x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.00 Million) by net assets ($12.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CRIS stock market capitalisation for the company's overall valuation and market capitalisation.
Curis Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Curis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Curis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curis Inc ranked by their cash flow conversion efficiency. Explore CRIS cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Abrdn UK Smaller Companies Growth Trust PLC
LSE:AUSC
|
0.008x |
|
Hansa Trust
LSE:HAN
|
0.324x |
|
Vistal Gdynia
WAR:VTL
|
0.003x |
|
GIVOT OLAM OIL EXP ILS1
TA:GIVO-L
|
0.253x |
|
Conduit Pharmaceuticals Inc.
NASDAQ:CDT
|
0.031x |
|
Transition Evergreen
PA:EGR
|
0.008x |
|
FAT Brands Inc
NASDAQ:FAT
|
0.024x |
|
Riwi Corp
V:RIWI
|
-0.140x |
Annual Cash Flow Conversion Efficiency for Curis Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Curis Inc from 1999 to 2025. View Curis Inc (CRIS) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.46 Million | $-27.20 Million | -4.980x | -175.50% |
| 2024-12-31 | $-6.00 Million | $-39.56 Million | 6.596x | +437.58% |
| 2023-12-31 | $19.67 Million | $-38.43 Million | -1.954x | -67.40% |
| 2022-12-31 | $46.55 Million | $-54.34 Million | -1.167x | -181.44% |
| 2021-12-31 | $90.71 Million | $-37.62 Million | -0.415x | -110.55% |
| 2020-12-31 | $130.67 Million | $-25.74 Million | -0.197x | -125.49% |
| 2019-12-31 | $-33.91 Million | $-26.20 Million | 0.773x | -88.44% |
| 2018-12-31 | $-4.50 Million | $-30.07 Million | 6.687x | +431.80% |
| 2017-12-31 | $23.99 Million | $-48.35 Million | -2.015x | -64.70% |
| 2016-12-31 | $29.27 Million | $-35.81 Million | -1.224x | -164.09% |
| 2015-12-31 | $64.51 Million | $-29.89 Million | -0.463x | +17.92% |
| 2014-12-31 | $29.78 Million | $-16.81 Million | -0.564x | -167.31% |
| 2013-12-31 | $45.17 Million | $-9.54 Million | -0.211x | +52.37% |
| 2012-12-31 | $34.27 Million | $-15.19 Million | -0.443x | -287.44% |
| 2011-12-31 | $39.88 Million | $-4.56 Million | -0.114x | -219.74% |
| 2010-12-31 | $45.52 Million | $-1.63 Million | -0.036x | +84.41% |
| 2009-12-31 | $33.05 Million | $-7.59 Million | -0.230x | +31.30% |
| 2008-12-31 | $37.22 Million | $-12.44 Million | -0.334x | -82.17% |
| 2007-12-31 | $46.84 Million | $-8.59 Million | -0.183x | -10.14% |
| 2006-12-31 | $35.90 Million | $-5.98 Million | -0.167x | +22.23% |
| 2005-12-31 | $38.00 Million | $-8.14 Million | -0.214x | -42.93% |
| 2004-12-31 | $48.91 Million | $-7.33 Million | -0.150x | +40.33% |
| 2003-12-31 | $38.87 Million | $-9.76 Million | -0.251x | +32.68% |
| 2002-12-31 | $18.54 Million | $-6.92 Million | -0.373x | -51.50% |
| 2001-12-31 | $101.02 Million | $-24.88 Million | -0.246x | -76.21% |
| 2000-12-31 | $168.81 Million | $-23.59 Million | -0.140x | +77.84% |
| 1999-12-31 | $23.42 Million | $-14.77 Million | -0.631x | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. … Read more